About Zafrens

Zafrens utilizes nanofabrication to analyze and manipulate diverse cell populations at single-cell resolution, generating paired longitudinal imaging and sequencing data. This technology enables high-throughput drug discovery across various modalities, enhancing our understanding of cellular behavior and facilitating scientific discoveries at an unprecedented scale.

```xml <problem> Current methods for drug discovery and cellular analysis lack the throughput and resolution needed to fully understand cellular behavior and identify effective drug candidates across diverse modalities. Traditional approaches often fail to capture the dynamic interplay between cellular phenotypes, genotypes, and responses to various perturbations at a single-cell level. </problem> <solution> Zafrens employs nanofabrication techniques to analyze and manipulate large populations of cells at single-cell resolution, generating paired longitudinal imaging and sequencing data. This high-throughput approach enables researchers to link cellular phenotypes with their corresponding genotypes and responses to a library of perturbations. By integrating these multi-modal data streams, Zafrens facilitates the identification of novel drug targets and the development of more effective therapies. The platform's ability to perform longitudinal co-cultures and simultaneous phenotypic and molecular high-throughput screening (HTS) provides a comprehensive understanding of cellular behavior. </solution> <features> - Nanofabrication-based platform for single-cell analysis and manipulation - Longitudinal co-cultures of different cell types in various assays - Active-seq: Mapping molecular states of cells to their functional manifestation - Active-Drug-seq: Simultaneous phenotypic and molecular HTS - Paired longitudinal imaging and sequencing data output - High-throughput screening of 50,000 - 200,000 cells and/or drugs per experiment </features> <target_audience> The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery, personalized medicine, and basic cellular research. </target_audience> ```

What does Zafrens do?

When was Zafrens founded?

Zafrens was founded in 2022.

Who founded Zafrens?

Zafrens was founded by Helen Liang.

Helen Liang - Founder

Founded

2022

Employees

34 employees

Looking for specific startups?

Try our free semantic startup search

Zafrens

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

zafrens.com 2K+

Crunchbase

Founded 2022

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (30+)

Helen Liang

Founder

Company Description

Problem

Current methods for drug discovery and cellular analysis lack the throughput and resolution needed to fully understand cellular behavior and identify effective drug candidates across diverse modalities. Traditional approaches often fail to capture the dynamic interplay between cellular phenotypes, genotypes, and responses to various perturbations at a single-cell level.

Solution

Zafrens employs nanofabrication techniques to analyze and manipulate large populations of cells at single-cell resolution, generating paired longitudinal imaging and sequencing data. This high-throughput approach enables researchers to link cellular phenotypes with their corresponding genotypes and responses to a library of perturbations. By integrating these multi-modal data streams, Zafrens facilitates the identification of novel drug targets and the development of more effective therapies. The platform's ability to perform longitudinal co-cultures and simultaneous phenotypic and molecular high-throughput screening (HTS) provides a comprehensive understanding of cellular behavior.

Features

Nanofabrication-based platform for single-cell analysis and manipulation

Longitudinal co-cultures of different cell types in various assays

Active-seq: Mapping molecular states of cells to their functional manifestation

Active-Drug-seq: Simultaneous phenotypic and molecular HTS

Paired longitudinal imaging and sequencing data output

High-throughput screening of 50,000 - 200,000 cells and/or drugs per experiment

Target Audience

The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery, personalized medicine, and basic cellular research.